Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy
Microbiology and Immunology, Volume 55, No. 6, Year 2011
Notification
URL copied to clipboard!
Description
Both host and viral factors have been implicated in influencing the response to pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy for hepatitis C virus (HCV) infection. Among the viral factors, sequence heterogeneity within NS5A and core regions has been proposed. This study aimed to clarify the relationship between virological responses to PEG-IFN/RBV therapy and sequence heterogeneity within NS5A, including the IFN/RBV resistance-determining region (IRRDR), the interferon sensitivity-determining region (ISDR) and the core region. Pretreatment sequences of NS5A and the core regions were analyzed in 57 HCV-1b-infected patients who were to be treated with PEG-IFN/RBV. Of 40 patients infected with HCV having an IRRDR with four or more mutations (IRRDR ≥ 4), 28 (70%) patients achieved a sustained virological response (SVR). On the other hand, only 4 (24%) of 17 patients infected with HCV having an IRRDR with three or fewer mutations (IRRDR ≤ 3) achieved a SVR (P= 0.001). Similarly, 22 (71%) of 31 patients infected with HCV and having an ISDR with one or more mutations (ISDR ≥ 1) achieved a SVR while 10 (38%) of 26 patients infected with HCV and having an ISDR without any mutations (ISDR = 0) achieved a SVR (P= 0.014). As for the core region, there was significant correlation between a single mutation at position 70 (Gln70) and non-SVR (P= 0.02). Notably, Gln70 was more prominently associated with the null response (P= 0.0007). In conclusion, sequence heterogeneity within the IRRDR and ISDR, and a single point mutation at position 70 of the core region of HCV-1b are likely to be correlated with virological responses to PEG-IFN/RBV therapy. © 2011 The Societies and Blackwell Publishing Asia Pty Ltd.
Authors & Co-Authors
El-Shamy, Ahmed M.
Japan, Kobe
Graduate School of Medicine
Egypt, Ismailia
Faculty of Veterinary Medicine
Shoji, Ikuo
Japan, Kobe
Graduate School of Medicine
Saito, Takafumi
Japan, Yamagata
Yamagata University Faculty of Medicine
Watanabe, Hisayoshi
Japan, Yamagata
Yamagata University Faculty of Medicine
Ide, Yoshihiro
Japan, Kobe
Graduate School of Medicine
Deng, Lin
Japan, Kobe
Graduate School of Medicine
Kawata, Sumio
Japan, Yamagata
Yamagata University Faculty of Medicine
Hotta, Haku
Japan, Kobe
Graduate School of Medicine
Statistics
Citations: 21
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1111/j.1348-0421.2011.00331.x
e-ISSN:
13480421
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases